# 1 From genome to phenome via the proteome: broad capture, antibody-based proteomics to

# 2 explore disease mechanisms

- 3 Mine Koprulu<sup>1</sup>, Julia Carrasco-Zanini<sup>1</sup>, Eleanor Wheeler<sup>1</sup>, Sam Lockhart<sup>1,2</sup>, Nicola D. Kerrison<sup>1</sup>,
- 4 Nicholas J. Wareham<sup>1</sup>, Maik Pietzner<sup>1,3</sup>, Claudia Langenberg<sup>1,3</sup>
- 5 1. MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of
- 6 Metabolic Science, Cambridge, CB2 0QQ, UK.
- 2. MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of
   Cambridge, Cambridge, UK
- 9 3. Computational Medicine, Berlin Institute of Health at Charité-Universitätsmedizin Berlin,
- 10 10117 Berlin, Germany.
- 11
- 12 Correspondence to:
- 13 Claudia Langenberg (claudia.langenberg@mrc-epid.cam.ac.uk), MRC Epidemiology Unit,
- 14 University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge,
- 15 CB2 0QQ, UK.

#### 16 Abstract

17 Studying the plasma proteome as the intermediate layer between the genome and the phenome has the potential to identify disease causing genes and proteins and to improve our 18 19 understanding of the underlying mechanisms. Here, we conducted a *cis*-focused proteogenomic analysis of 2,923 plasma proteins measured in 1,180 individuals using novel antibody-based 20 21 assays (Olink<sup>®</sup> Explore 1536 and Explore Expansion) to identify disease causing genes and proteins across the human phenome. We describe 1,553 distinct credible sets of protein 22 quantitative trait loci (pQTL), of which 256 contained cis-pQTLs not previously reported. We 23 24 identify 224 cis-pQTLs shared with 578 unique health outcomes using statistical colocalization, including, gastrin releasing peptide (GRP) as a potential therapeutic target for type 2 diabetes. 25 26 We observed convergence of phenotypic consequences of cis-pQTLs and rare loss-of-function gene burden for twelve protein coding genes (e.g., TIMD4 and low-density lipoprotein 27 metabolism), highlighting the complementary nature of both approaches for drug target 28 29 prioritization. Proteogenomic evidence also improved causal gene assignment at 40% (n=192) of overlapping GWAS loci, including *DKKL1* as the candidate causal gene for multiple sclerosis. 30

Our findings demonstrate the ability of broad capture, high-throughput proteomic technologies to robustly identify new gene-protein-disease links, provide mechanistic insight, and add value to existing GWASs by enabling and refining causal gene assignment.

#### 35 Introduction

36 Rare and common sequence variation across the genome contributes to the risk of most human 37 diseases investigated to date (1). However, the translation of the many established and emerging 38 genome-to-phenome links is limited by the uncertainty around the underlying causal genes. This 39 presents a major limitation for experimental follow-up, mechanistic understanding, and use of the emerging genomic evidence in drug development. Different approaches, such as integration 40 41 of tissue-specific gene expression data (2), experimentally derived functional genomic data such 42 as ChIP-seq or ATAC-seq (3), or functional characterization of candidate variants using CRISPR screens in cellular models (4) have been used to address this gap and to identify likely causal 43 44 genes at risk loci. However, complex regulatory processes take place at each stage of 45 transcription and translation, which often leads to low correlation between transcripts and proteins, and cellular models can only approximate complex human biology. Compared to these 46 methods, the proteogenomic approach has the advantage of focusing on the biologically active 47 entity - the protein. 48

The development of broad-capture proteomic assays, targeting thousands of proteins in parallel. 49 now enables proteogenomic approaches which can efficiently identify causal genes by 50 systematically testing for shared genetic regulation of protein levels or function and disease 51 52 susceptibility. This has catalyzed substantial advances in the identification of a) causal genes and 53 proteins underlying established disease 'loci', and b) molecular 'hubs' that connect the genome not to one but many diseases through the encoded protein (5-18). Previous large-scale 54 proteogenomic studies covering thousands of proteins have almost exclusively used aptamer-55 based assays (10, 11, 15, 16). Correlations of protein measures from aptamer versus antibody-56 based technologies have been shown to vary widely, and proteogenomic results are concordant 57 for around only 65% based on around 900 overlapping proteins targets (16). To date, antibody-58 based proteomic assays have only been available for selected protein panels at scale (9, 14, 18), 59 60 but this is changing with the availability of the Olink<sup>®</sup> Explore 1536 and Olink<sup>®</sup> Explore Expansion assays measuring ~1,400 proteins each. 61

The UK Biobank Pharma Proteomics Project (UKB-PPP) project which measured ~1,400 proteins 62 using Olink<sup>®</sup> Explore 1536 assay in over 50,000 participants successfully demonstrated the power 63 64 of scaling up by cataloguing over 10,000 mainly novel pQTLs (17). However, this study provided few insights about the translational potential of pQTLs to systematically inform candidate gene 65 annotation at known risk loci and more importantly, to reveal novel biological roles of proteins 66 for human health at scale. UKB-PPP and others did demonstrate that genuine and biologically 67 relevant protein quantitative trait loci (pQTL) can be discovered in as few as hundreds of 68 individuals (14, 17, 19), suggesting that broader proteomic coverage in even small-scale 69 proteogenomic studies can make substantial advances to the understanding of diseases if 70 71 integrated with large-scale phenomic data.

Here we generate antibody-based proteomic data using the Olink<sup>®</sup> Explore 1536 and Explore Expansion assays to capture 2,923 proteins in 1,180 individuals. We perform genetic finemapping at protein coding genes (±500kb) and enhance the understanding of disease mechanisms by systematically integrating cis-pQTLs with thousands of diseases and health measures to (a) refine the candidate causal gene assignment at existing disease susceptibility loci at scale and (b) identify novel disease mechanisms in phenome-wide colocalization analyses.

#### 79 Results

#### 80 Identification and fine-mapping of cis-proteogenomic signals for 2,923 protein targets

We adopted a Bayesian fine-mapping strategy (20) to identify proximal acting genetic variants 81 (cis-pQTLs, ±500kb around the protein coding gene) that were associated with plasma abundance 82 of 2,923 proteins measured in 1,180 participants of the EPIC-Norfolk cohort (21) (Supplementary 83 Table 1). We identified a total of 1,553 independent credible sets for 914 unique protein targets 84 for which sentinel variants reached genome-wide significance ( $p < 5x10^{-8}$ ) when modelled jointly 85 at each protein coding locus (Fig. 1A, Supplementary Table 2). The number of independent 86 87 credible sets for each protein target ranged between one and eight (mean=1.64, IQR=1-2), illustrating wide-spread allelic heterogeneity at protein coding loci. We observed a high 88 89 replication rate (89.9%, 910 out of 1,013) for credible sets of 590 protein targets overlapping with the UKBB-PPP effort. Conversely, we identified 4.5% of the 20,540 reported signals in as few as 90 1,200 participants that were reported based on more than 35,000 participants of the UKB-PPP. 91 92 A total of 256 (16.5%) credible sets contained cis-pQTLs not previously reported, including 131 proteins that have not been measured by previous platforms (Fig. 1B) (5-18). Notably 125 signals 93 94 were for 101 previously targeted proteins, the majority of which (n=92 proteins) have been 95 targeted using non-antibody-based technologies in samples sizes up to 30 times larger than ours (10, 11, 15, 16) (Fig. 1B). 96

Effect size and minor allele frequency distributions of unreported cis-pQTLs were comparable to
the 1,297 (83.5%) successfully replicated cis-pQTLs (5-18) (Supplementary Table 2), illustrating
that complementary proteomic technologies can still identify genetic variants that would have
been anticipated to be seen in previous studies (Fig. 1A, Fig. 1D).

We observed a strong inverse relationship between the absolute effect sizes of cis-pQTLs and the log<sub>10</sub>-transformed frequencies of their minor alleles (r=-0.78; p<1x10<sup>-300</sup>), likely due to the more severe predicted consequences of rarer alleles, such as stop-gain mutations (**Fig. 1B-C**). We also report 482 cis-pQTLs with a minor allele frequency (MAF) above 5% with large absolute effect sizes (range 0.5-1.72 s.d. per allele), suggesting strong genetic control of the associated proteins. Of these, less than half (35.9%) were protein altering variants themselves or were in strong

107 linkage disequilibrium (LD;  $r^2>0.6$ ) with one, potentially affecting the binding affinity of 108 antibodies. Proteins with at least one significant cis-pQTL were enriched for characteristics of 109 secreted proteins, like the presence of disulfide-bonds (odds ratio: 4.47; p-value=3.0x10<sup>-74</sup>) or 110 glycosylation sites (odds ratio: 2.22; p-value=1.1x10<sup>-13</sup>), but depleted of sites for posttranslational 111 modifications that are important for intracellular signaling, like phosphorylation (odds ratio: 0.42; 112 p-value=5.5x10<sup>-14</sup>) or ubiquitination (odds ratio: 0.30; p-value=4.2x10<sup>-11</sup>). 113 Finally, for more than half of the protein targets (n=532) with at least one pQTL, we observed

strong evidence of colocalization (PP>80%) between a cis-pQTL and the corresponding gene expression QTL (eQTL) signal in at least one out of 49 tissues of the GTEx resource (Supplementary Table 3). These results suggest altered expression of protein coding genes in one

117 or multiple tissues as the major source for cis associations observed with plasma protein levels.

118



Figure 1: Genetic regulation of 2,923 proteins measured by the Olink Explore 1536 and Olink Explore Expansion platforms in 1,180 individuals. Previously unreported and reported pQTLs are represented with a filled and hollow circle, respectively. Only the variants which are genome-wide significant (pvalue<5x10<sup>-8</sup>) in the joint model (see Methods) are presented. **A. Miami plot representing the independent lead cis-pQTLs identified through Bayesian fine-mapping for 914 unique proteins.** Shown are p-values from a linear regression model modelling all identified credible set variants for a given protein target jointly. *Top*: Lead cis-pQTL signals unreported to date. *Bottom*: Lead cis-pQTL signals which were in

130 linkage disequilibrium (LD;  $r^2$ >0.5) with a previously reported pQTL. **B. Minor allele frequency vs effect** 131 size of unreported pQTL signals, coloured by whether the protein has previously been targeted. 132 Unreported pQTL signals for a previously targeted protein are coloured grey and those for a previously 133 untargeted protein are coloured orange. C. Minor allele frequency vs effect size of unreported pQTL 134 signals, coloured by most severe variant consequence prediction. The colour coding represents the most 135 severe Variant Effect Predictor (22) consequence of the lead cis-pQTL, or variants in LD ( $r^2$ >0.6) within the 136 protein encoding gene. The most severe consequence is coloured red (Ensembl consequence rank = 1) 137 and the least severe consequence is coloured blue (Ensembl consequence rank = 37). D. Minor allele frequency vs effect size of reported pQTL signals, coloured by most severe variant prediction. The colour 138 139 coding represents the most severe Variant Effect Predictor (22) consequence of the lead cis-pQTL, or 140 variants in LD ( $r^2>0.6$ ) with the lead cis-pQTL within the protein encoding gene. The most severe 141 consequence is coloured red (Ensembl consequence rank = 1) and the least severe consequence is coloured blue (Ensembl consequence rank = 37). 142

143

#### 144 From genome to phenome via the proteome

The genome is linked to the phenome via the proteome and the translational potential of pQTLs 145 is due to their ability to link insights about the genetic regulation of protein levels and function 146 to diseases (15). We identified 1,110 robust protein - phenotype pairs (Fig. 2; posterior 147 148 probability [PP] > 80% of a shared genetic signal) comprising 224 protein targets for 575 unique traits by systematically testing for a shared genetic architecture at protein coding loci (±500kb) 149 across the phenome (see Methods; Supplementary Table 4). This included well-described 150 151 examples, such as UMOD and kidney disease or established drug targets like PCSK9 and LDL-152 cholesterol, but importantly 93 protein targets connected with at least one phenotype that have been missed by previous aptamer-based efforts. 153



154

155

Figure 2: Protein – disease network. Results from phenome-wide colocalization at protein coding 156 157 loci (±500kb) are shown. For simplicity, only proteins with at least one binary outcome (i.e., 158 mainly diseases) association are included. Proteins are presented with a square, binary outcomes 159 are presented with large circles, and continuous outcomes are presented with small circles. The colour for the circles present the trait category. Edges between proteins and phenotypes 160 represent strong evidence for a shared genetic signal (PP>80% and LD between regional sentinel 161 variants >0.8). Effect directions are indicated by the line type (solid = higher protein abundance, 162 increased risk, dashed = higher protein abundance, reduced risk) and derived based on the lead 163 cis-pQTL at the corresponding locus. The full list of colocalization results can be found in 164 Supplementary Table 4. Abbreviations: GIT, gastrointestinal tract. 165

166

167 One of the examples is gastrin releasing peptide (GRP, encoded by GRP), for which we observed 168 strong evidence of colocalization (posterior probability [PP] =82.5%) between plasma levels and 169 type 2 diabetes (T2D) risk at an established GWAS locus (18q21) for which different genes had 170 been prioritized, including SEC11C, GRP, and MC4R (23-25). The GRP-increasing G-allele of the 171 lead cis-pQTL (rs1517035; MAF=0.18) was associated with a reduced risk for T2D (odds ratio=0.96, p-value=7.8x10<sup>-10</sup>). GRP is a neuropeptide named for its ability to stimulate secretion 172 173 of the gastric acid secretagogue, gastrin, in the stomach (26, 27), but it is likely involved in other metabolic pathways. We obtained strong evidence that GRP likely mediates T2D risk via an effect 174 175 on overall obesity, based on the convergence of evidence from mice studies, human trials, and 176 human genetic data. We established a shared genetic signal between plasma GRP, body mass 177 index and fat, and T2D risk using multi-trait colocalization with coherent effect directions (Fig. 3). 178 GRP induces satiety in mice via its cognate GRP receptor (Grpr) (28, 29). Further, mice lacking 179 Grpr show impaired glucose tolerance after gastric glucose administration (30) and gain excess 180 body weight under ad libidum conditions (29). These observations have been corroborated by 181 human trials, in which treatment with human recombinant GRP (hrGRP) led to weight loss 182 through reduced food intake (31). In summary, our results motivate investigations into hrGRP for 183 appetite control and body weight lowering to possibly assist in T2D management and remission, 184 an approach similar to recently implemented treatment strategies targeting incretins, like GLP-185 1, and associated receptors, with preliminary evidence of an additive effect in rats (32).

186



188

Figure 3: Stacked regional association plots for the multi-trait colocalization. A. Stacked regional 189 190 association plots for the multi-trait colocalization of the GRP cis-pQTL with gynoid fat, android fat, total 191 body fat, body mass index and type 2 diabetes. The top candidate SNP highlighted by multi-trait 192 colocalization (rs7243357) and lead cis-pQTL for GRP (rs1517035) are in strong LD (r2=0.8). Gynoid fat, 193 android fat and total body fat phenotypes are based on UK Biobank and were analysed in-house using BOLT-LMM (33). B. Stacked regional association plot the multi-trait colocalization of the FGFR4 cis-pQTL 194 195 with type 2 diabetes in East Asian populations. Red colouring represents a positive effect direction in reference to the protein increasing allele for GRP whereas blue represent an inverse association. The hue 196 of the colour represents the strength of  $r^2$  representing the LD structure, as indicated on the legend. 197 European Type 2 diabetes summary statistics were obtained from dbGAP Million Veteran Program (MVP) 198 199 European subset (n<sub>cases</sub>= 148,726, n<sub>controls</sub>= 965,732) (34). East Asian Type 2 diabetes summary statistics 200 were obtained from Mahajan et al (2022) ( $n_{cases}$  = 56,268 ,  $n_{controls}$  = 227,155) (25). The body mass index 201 summary statistics were obtained from Pulit et al. (2019) (n=806,834) (35).

202

Several T2D loci have been reported to be specific to certain ancestries (23-25). In the absence 204 205 of strong differences in allele frequency, such ancestry specific effects could be caused by a 206 variety of different factors, including environmental factors such as dietary intake. We obtained robust evidence that FGFR4 is the candidate causal gene at the East Asian-specific FGFR4-NSD1 207 locus supported by a high posterior probability (PP=97%) for a shared genetic signal with plasma 208 levels of the gene product fibroblast growth factor receptor 4 (FGFR4) and trans-ancestral 209 conserved LD between regional sentinel variants (r<sup>2</sup>>0.96; **Fig. 3**). The protein-increasing A-allele 210 of the lead cis-pQTL (rs351855, beta= 1.01, p-value=9.8x10<sup>-234</sup>, EAF<sub>European</sub>=0.30, EAF<sub>EastAsian</sub>=0.46) 211 was associated with an increased risk for T2D (beta=0.05, p-value=1.1x10<sup>-7</sup>). Candidate gene 212 213 studies have implicated rs351855 (p.G388R) in cancer susceptibility (36-38), and subsequent mechanistic studies showed a gain of function of the mutant FGFR4 by binding transducer and 214 activator of transcription 3 (STAT3) (39). While we found no evidence for an association to cancer, 215 there are different studies that support our observation of FGFR4 in T2D-related pathways 216 including hepatic glucose, bile, and lipid metabolism, and possibly insulin signaling in a diet-217 dependent manner (40-43). Briefly, *Fqfr4<sup>-/-</sup>* mice fed a normal chow diet exhibit insulin resistance 218 and impaired glucose tolerance compared to wild-type controls, however, this difference is not 219 220 observed in high-fat diet fed mice. A similar masked genetic effect is seen with the mutant protein in mice and small observational studies in humans (44). The ability of diet to obscure genetic 221 effects may explain the ancestral-specific effect in the absence of strong differences in allele 222 frequencies, with high-fat diet conditions being substantially more common in Western-style 223 countries of predominantly European ancestry compared to East Asia (45), in particular Japan, in 224 line with Biobank Japan (p-value<sub>T2D</sub>< $7.6x10^{-11}$ ) being the largest contributing population to the 225 East Asian T2D meta-analysis (25). 226

227

# Proteogenomic guided annotation of genes at loci reported for diseases and traits related to human health

Annotation of the candidate causal genes at disease susceptibility loci is the major bottleneck in the translation of GWAS into biological and possibly clinical insights (46). We exploited the

genomic proximity between cis-pQTLs and the protein coding gene for gene annotation by 232 233 systematically overlapping identified credible sets in this study with reported risk loci (p<5x10<sup>-8</sup>) 234 from the GWAS catalog (downloaded on 23/03/2022; (1)). We identified 480 credible sets targeting 395 unique proteins (43.2% of all, 914 unique protein targets) for which the lead cis-235 pQTL or a proxy (r<sup>2</sup>>0.8) had been reported for one or more of 5,391 collated traits in the GWAS 236 catalog (Fig. 4 and Supplemental Tab. 5, see Methods). For 40% (n=192) of those, we prioritized 237 a gene that was different from the one originally reported, of which 50% (n=96) were not the 238 239 gene nearest to the GWAS sentinel variant. We further refined a longer list of putative causal genes to a single one for an additional 31 cis-regions (6.5%). These results exemplify the unique 240 241 potential of cis-pQTLs for gene annotation of loci reported across diseases and traits related to human health (Fig. 4 and Supplemental Tab. 5), with one example outlined in more detail below. 242

243 Multiple Sclerosis (MS) is an autoimmune, inflammatory, and neurodegenerative disease of the 244 central nervous system that is caused by both genetic and strong environmental factors (47). A 245 strong signal at 19q13.33 is one of 233 reported GWAS loci (48). Several variants in high LD (r<sup>2</sup>>0.9) reported for this locus have been linked to different candidate causal genes, including 246 247 DKKL1, CD37, and SLC6A16 which was the most recently annotated gene based on a sophisticated 248 ensemble of methods (48). We identify a shared genetic signal (PP=96.1%, Supplemental Fig. 1) 249 between dickkopf like acrosomal protein 1 (DKKL1), encoded by DKKL1, and MS at this locus, led by a cis-pQTL (rs2288480; MAF=0.25) in high LD ( $r^2$ =0.97) with the lead MS variant (rs1465697; 250 251 MAF=0.33, OR=1.09, p-value= $3x10^{-18}$ ). We note that the lead cis-pQTL was also in LD ( $r^2=0.97$ ) with a recently identified variant at the same locus for systemic lupus erythematosus (SLE) among 252 253 East Asians (49).

The lead cis-pQTL is in strong LD ( $r^2>0.8$ ) with a cluster of three common missense variants (rs2288481, rs2303759, and rs1054770) that might impair protein function or processing. Little is known about the biological role of DKKL1 in general, but a non-essential role in spermatogenesis has been described (50). However, a link towards MS and/or SLE might be conceivable via a possible role of DKKL1 in adaptive immunity and hence the inflammatory component of MS. Briefly, *DKKL1* expression is enriched among memory B-cells (51) and an independent secondary cis-pQTL (rs66532151, MAF=22.4%) for DKKL1 tagged ( $r^2>0.96$ ) a cluster

of variants associated with different characteristics of CD20<sup>+</sup> memory B-cells (52). This cis-pQTL (rs66532151) was associated with MS at p-value=3.4x10<sup>-7</sup>, providing late genetic evidence for depletion of B-cells being one of the most effective treatments for MS, a therapeutic strategy that originally emerged from clinical and neuropathological studies (53, 54). Further follow-up studies are needed to clarify a possible role of DKKL1 in immune cells and whether DKKL1 may play a role in B-cell hyperactivity observed in MS (53).

- 267
- 268
- 269
- 270



#### 271

Figure 4: Candidate causal gene assignment at reported GWAS loci using pQTLs. The overlap between existing GWAS risk loci and pQTL loci (n=480) are marked on the human chromosome karyotypes (chromosomes 1-22). The locus is coloured orange if the pQTL provides a novel candidate causal gene assignment for one or more traits, light blue if it refines a candidate causal gene from a longer list of reported or closest genes, and dark blue if it confirms the candidate causal gene assignment provided by the GWAS.

278

279 Multiple independent genetic variants associated with the same protein target at the same locus, 280 so-called allelic heterogeneity, provides the highest confidence in gene assignment but can also 281 highlight differential biological roles for the same protein. We observed 73 such protein targets

with two or more credible sets including distinct GWAS variants for related and unrelated traits. 282 283 For example, we discovered three distinct credible sets for plasma levels of interleukin 34 (IL-34) 284 at 16q22.1. Two contained independent ( $r^2$ =0.07) lead cis-pQTL variants with distinct structural consequences on the protein, that were also associated with two distinct outcomes – Alzheimer's 285 disease (55) and childhood obesity (56) (Fig. 5). rs4985556 is associated with increased risk for 286 Alzheimer's disease (MAF=12.2%; beta=0.07, p-value<2.3x10<sup>-8</sup>) and introduces a premature stop 287 (p.Tyr213Ter), truncating the protein and likely affecting dimerization and possibly secretion. 288 rs8046424 (alternate allele: C; r2=0.96 with lead sentinel childhood obesity variant rs4985555) is 289 290 associated with reduced childhood obesity (MAF = 48.2%; beta=-0.008, p-value<4.4x10<sup>-9</sup>). It is a 291 missense variant (p.Glu123Gln) of moderate consequence (CADD score 11.6) that maps to a binding domain of the cognate IL-34 receptor CSF-1R (57). Therefore, both variants will likely 292 293 strongly (rs4985556) or moderately (rs8046424) attenuate signaling via CSF-1R, which has been shown to drive cerebrovascular pathologies that are common in Alzheimer's disease (58). While 294 the gradient of structural consequences translates into a graded effect on Alzheimer's disease 295 (rs8046424, beta=0.03, p<3.6x10<sup>-4</sup>), the absence of any effect of the more detrimental variant 296 (rs4985556) on childhood obesity (beta=-0.001, p=0.59) might point to a different, yet to be 297 298 defined, pathway.

299 We observed a similar segregation of phenotypes across distinct cis-pQTLs for alpha-L-300 iduronidase encoded at IDUA. Briefly, three out of four detected credible sets contained GWAS 301 risk loci or strong proxies (r<sup>2</sup>>0.8) for fractures (59) (rs115134980; MAF=16.1%; beta=-0.06, p-302 value=7.4x10<sup>-12</sup>), waist-to-hip ratio adjusted for BMI (60) and inflammatory diseases (61) (rs11724804; MAF=44.7%; beta=-0.017, p-value<7.6x10<sup>-21</sup>), as well as type 1 diabetes (62) 303 (rs3796622; MAF=35.2%; beta=-0.07, p-value<1.7x10<sup>-7</sup>) (Fig. 5). Alpha-L-iduronidase is essential 304 for the breakdown of glycosaminoglycans within lysosomes and numerous rare pathogenic 305 306 variants within IDUA are known to cause accumulation of glycosaminoglycans in lysosomes 307 (mucopolysaccharidosis type I [MPS-1]). Patients present with a wide spectrum of complications, 308 such as skeletal deformities or organomegaly, that has been attributed to the variable impact of mutations on enzyme activity, with nonsense mutations causing most severe diseases (Hurler 309 310 syndrome) (63). While skeletal abnormalities in rare disease patients may relate to bone

phenotypes seen for the common cis-pQTL, there are no reports for an elevated risk for inflammatory or autoimmune disease among MPS-1 patients or other evidence from rare variant analysis. Tissue-dependent effects of common variants might be one explanation for the different phenotypes linked to distinct cis-pQTLs for alpha-L-iduronidase.

315



317 Figure 5: Allelic heterogeneity at protein coding loci translates into distinct phenotypic consequences 318 at IL34 and IDUA. Left Regional association plots centered around IL34 (±200kb) for plasma interleukin 34 319 levels, comparative body size at age 10 (56), and Alzheimer's disease (55). Shown are association statistics 320 (p-values) from genome-wide association analysis. Single genetic variants were coloured based on LD with 321 two distinct cis-pQTLs (rs4985556 – orange; rs8046424 – purple). Right Regional associations plots 322 centered around IDUA (±400kb) for plasma alpha-L-iduronidase levels, type 1 diabetes (62), waist-to-hip ratio (WHR) adjusted for body mass index (BMI) (60), and risk of fractures (59). Shown are association 323 324 statistics (p-values) from genome-wide association analysis. Single genetic variants were coloured based 325 on LD with three distinct cis-pQTLs (rs3796522 – orange; rs115134980 – purple; rs11724804 – green). 326 Lead cis-pQTLs are highlighted by hollow diamonds.

327

316

# Phenotypic convergence of rare variant burden and common cis-pQTLs for protein coding genes

330 Much effort and funding has been invested into biobank-scale whole-exome sequencing studies

331 (ExWAS) to identify rare deleterious genetic variants and novel disease candidate genes for the

development of treatment strategies (64, 65). However, it is unknown how efforts focusing on

the rare deleterious end of gene (and protein) dysfunction relate to less extreme alterations of
protein levels or function. To explore whether evidence from ExWAS and our cis-based phenomewide colocalization analyses converge for disease-linked genes, we systematically integrated our
results with those from a recent ExWAS among ~450,000 UK Biobank participants across almost
4,000 phenotypes (64).

Among 2,939 protein coding genes covered by the Olink Explore 1536 and Explore Expansion 338 339 platforms, 40 (1.3%) showed evidence for phenotypic associations with a rare variant gene-340 burden and statistical colocalization with a cis-pQTL, whereas 281 and 184 protein coding genes were linked to phenotypes through ExWAS or cis-pQTLs only, respectively (Fig. 6). Out of the 40 341 342 overlapping genes, we observed phenotypic convergence for only 12 genes across 21 phenotypes 343 following manual review to harmonize phenotype definitions (Supplementary Tab. 6). These results clearly exemplify the complementary nature of both approaches and the unique ability of 344 345 bespoke proteogenomic experiments to prioritize disease mediators and hence putative 346 therapeutic targets.



348 Figure 6: Phenotypic convergence of rare variant burden and common cis-pQTLs for protein coding 349 genes and TIMD4 as an example. A. Venn diagram showing the number of genes with a significant rare 350 variant gene burden association (p<1E-06) with at least one trait (64) in blue and the number of genes 351 with a significant pQTL colocalization (PP>80%) with at least one trait in orange. All 2,939 unique genes 352 covered by Olink Explore 1536 and Explore Expansion assays were investigated. B. Forest plot comparing 353 the effect size estimates between TIMD4 cis-pQTL (rs58198139) and rare TIMD4 loss of function (LoF) 354 gene-burden results (variant group: missense and loss of function variants with a minor allele frequency 355 < 1%) for low density lipoprotein cholesterol, total cholesterol and triglyceride levels. Rare TIMD4 loss of function (LoF) gene-burden results are shown in blue and TIMD4 cis-pQTL associations are shown in 356 357 orange. C. Stacked regional plot of the multi-trait colocalization of TIMD4 cis-pQTL with lymphocyte 358 count, low density lipoprotein cholesterol, and triglycerides. Red colouring represents a positive effect 359 direction with protein increasing allele with TIMD4 whereas blue represent an inverse association. The hue of the colour represents the strength of  $r^2$  representing the LD structure, as indicated on the legend. 360

361

Convergence of phenotypic consequences from rare gene burden and common cis-pQTLs not 362 only provides compelling evidence for causal gene assignment but can establish dose-response 363 relationships that are an essential prerequisite for genetically informed drug discovery (66). We 364 observed such a dose-response relationship between putative functional consequences for T-cell 365 immunoglobulin and mucin domain containing 4 (TIMD4) and LDL-cholesterol as well as total 366 triglyceride, but not HDL-cholesterol levels in blood (Fig. 6C). The protein-decreasing T-allele of 367 the lead cis-pQTL (rs58198139) was associated with moderate effects on LDL-cholesterol in UK 368 Biobank (MAF=0.26; betaLDL=0.03, p-valueLDL=7x10<sup>-44</sup>), likely mediated by altered protein 369 expression, while the cumulative burden of rare loss-of-function variants was associated with 370 substantially higher LDL levels (beta<sub>LDL</sub>= 0.25, p-value<sub>LDL</sub>= 1.51x10<sup>-9</sup>, variant mask: predicted loss 371 of function and deleterious missense variants with MAF<1%), in line with this locus being one of 372 the earliest discovered loci for polygenic dyslipidemia but with few functional insights gained 373 since (67). TIMD4 is best known for its role in tissue-dependent macrophage efferocytosis of 374 375 apoptotic cells (68, 69) but does also participate in T-cell activation and recruitment (70). Accordingly, *Timd4<sup>-/-</sup>* mice show impaired macrophage phagocytosis and increased lymphocyte 376 cell counts (71), an observation recapitulated by our phenome-wide colocalization analyses 377 identifying an inverse association for the protein-decreasing T-allele for lymphocyte counts 378 (beta=1.02, p-value=1.4x10<sup>-12</sup>) with high certainty (PP = 97.5%). Circulating leucocytes and 379 resident M2 macrophages can take up cholesterol from circulating LDL particles and sequestered 380 381 lipoproteins in the vasculature, but classical pathways, like the LDL-receptor mediated uptake,

were shown, at least in mice, to have no substantial effect on plasma LDL-cholesterol levels (72). 382 383 In contrast, more recent work demonstrated the ability of TIMD4<sup>+</sup> adipose tissue macrophages 384 to significantly contribute to the regulation of post-prandial HDL-cholesterol levels in mice (73). While there were was no difference in triglycerides or non-HDL cholesterol following TIMD4 385 blockade, TIMD4 blockade inhibited LDL-induced lysosomal activity in vitro, suggesting a role for 386 TIMD4 in peripheral LDL cholesterol processing. These findings provide evidence of a role for 387 TIMD4 in the regulation of systemic lipoprotein metabolism, and taken together with our 388 proteogenomic findings, provide a compelling rationale to explore the role of TIMD4<sup>+</sup> 389 390 macrophages in systemic LDL cholesterol metabolism. In general, increased uptake of modified 391 LDL-cholesterol particles by resident macrophages contributes to atherosclerotic foam cell formation, a major cardiovascular risk factor (74). We observed no conclusive evidence that 392 either the cis-pQTL (protein decreasing T-allele; odds ratio [95% CI] = 1.04 [1.02-1.07], p-393 value=0.002) or the cumulative burden of the loss of function variation in the gene (odds ratio 394 [95% CI] = 1.3 [0.90-1.88], p-value=0.16) were associated with coronary artery disease (CAD; the 395 currently most powered GWAS for atherosclerotic consequences). However, our findings urge 396 further investigations into the functional role of TIMD4 in immune cell-mediated LDL-cholesterol 397 398 turnover and foam cell formation. Although the extent to which this mechanism can contribute to addressing CAD burden is currently unclear, blocking of TIMD4 using monoclonal antibodies 399 increased atherosclerotic lesion size in *Ldlr<sup>-/-</sup>* mice although in a possibly cholesterol-independent 400 manner (75). 401

#### 403 Discussion

Proteogenomic approaches have the potential to establish a direct link from rare and common variation in or closeby protein-encoding genes to human health via the protein product (5-18). Despite recent advances and early successes, the field is still in its infancy with respect to the scale and protein capture, with existing broad-capture technologies currently targeting less than a third of all proteins encoded in the human genome (5-18), not capturing posttranslational modifications, or providing absolute protein quantification.

Here we identified more than 200 novel cis-pQTLs that have not been reported so far, even in studies 30-times larger than ours using non-antibody-based technologies, by capitalizing on recent assay developments. The fact that we identified hundreds of cis-pQTLs for proteins that have been investigated in studies much larger than ours might be best explained by the need to develop further orthogonal methods to measure protein targets as we have outlined previously (14).

We demonstrate that systematic application of cis-pQTLs to large-scale genetic studies of human diseases can 1) guide causal gene annotation at GWAS loci (e.g., *DKKL1* for multiple sclerosis), 2) identify pathways that link genes to diseases guided by a protein-phenotype network, and 3) complement gene-burden testing of rare variants to discover novel biology. We highlight specific examples in more detail and share a large number of high-confidence protein–phenotype associations that provide a direct guide for functional follow-up and future investigations of variant protein with disease relevance about which little is known to date.

423 The vast majority (~90%) of genetic variants identified in GWASs reside in non-coding regions of 424 the genome (76), creating a challenge for variant-to-function annotation. In line with previous 425 studies, we demonstrate the efficiency and ability of cis-pQTLs to prioritize causal candidate genes including reassignments at 40% of overlapping loci. In contrast to other annotation 426 approaches, the particular value of the integration of proteogenomic studies lies in the 427 instrumentalization of the likely biological effector molecules. Studies using proteomic profiling 428 in disease relevant tissues or single cell-types are needed to further elucidate the mechanisms 429 underlying the many thousands of unassigned GWAS loci. 430

This study is a powerful demonstrating that even moderately sized proteomic studies can result 431 432 in the identification of novel biology when combined with bespoke analysis pipelines designed 433 for the identification of cis-pQTL and systematic integration and follow-up of disease GWAS summary statistics. Eventually multiple different technologies will be needed at scale to capture 434 not only proteins of interest but also the vast spectrum of proteoforms with possible distinct 435 phenotypic consequences (14). This prediction is supported by power calculations of the UKB-436 PPP (17), but also based on the observation that our study identified cis-pQTLs for genes that are 437 under less evolutionary constraint as indicated by higher observed/expected scores for missense 438 (+0.15; p-value=5.0x10<sup>-50</sup>) and loss-of-function (+0.22; p-value=7.5x10<sup>-51</sup>) variation in gnomAD 439 440 (77). This observation is in line with recent findings among eQTL studies (78).

441 We observed convergence of gene-phenotype associations between ExWAS and our proteogenomic approach only at a small number of genes. Gene identification with overlapping 442 443 or converging evidence, as shown for TIMD4, provides high confidence about the underlying 444 causal gene, while the incomplete overlap clearly indicates the complementary nature of both approaches for drug target prioritization. An important distinction between both approaches, 445 446 beyond the different genetic variants covered, is the ability of proteogenomics to emulate 447 protein variation across the whole spectrum of abundance and in some cases function, and not 448 only putative loss-of-function (rarely gain of function), which might explain differences seen in 449 phenotypic consequences between both approaches. In addition, in terms of practicality, 450 integration of pQTLs into colocalization and GWAS loci annotation enabled us to uncover unreported disease biology with a small sample size of 1,180 individuals, whereas substantially 451 452 larger sample sizes, even millions of individuals, are needed to reach enough power to detect 453 rare variant associations in ExWAS studies for disease endpoints (79).

Our study has some limitations that need to be considered. Affinity-based reagents allow for the quantification of protein abundance but are inherently limited to quantify the level of activity, although a general correspondence between the two can be assumed. This limits insights about the role of protein targets using a proteogenomic approach. Further, numerous posttranslational modifications can change the function and abundance of proteins but are currently not distinguishable using affinity reagents at scale. We deliberately decided to restrict genetic

analysis of protein targets to the corresponding protein coding regions (±500kb) for two reasons: 1) the high biological prior to identify genetic variants directly linked to protein function/abundance, and 2) to increase power for statistical analysis by limiting the multiple testing burden. Larger studies are needed to explore the spectrum of trans-pQTLs that have generally smaller effect sizes but can identify protein interaction partners and facilitate systematic dose-response analysis in the two-sample Mendelian randomization frameworks.

In summary, we demonstrate the clear potential of broad-capture proteogenomic studies to identify novel biological pathways that link protein-encoding genes to human diseases. Systematic integration of human genomic with proteomic and phenomic data enables such investigation even in relatively moderately sized studies and can help to prioritize targets and indications for the development of safe and effective therapeutic interventions.

471

#### 473 Materials and Methods

474

#### 475 *Study participants*

We measured protein levels among 1,180 participants of the European Prospective Investigation 476 477 into Cancer (EPIC)-Norfolk study, a cohort of 25,639 middle-aged, individuals from the general 478 population of Norfolk, a county in Eastern England which is a component of EPIC (21). The study 479 was approved by the Norfolk Research Ethics Committee (ref. 05/Q0101/191) and all participants 480 gave their informed written consent before entering the study. Information on lifestyle factors 481 and medical history was obtained from questionnaires as reported previously (21). We selected 482 a random sub-cohort of 771 participants and a set of 429 participants with selected incident events during follow-up for cost-efficient proteomic profiling. 483

484

## 485 *Proteomic profiling*

We used serum samples from the baseline assessment (1993 - 1997) that had been stored in 486 487 liquid nitrogen for proteomic profiling using the Olink Explore 1536 and Explore Expansion 488 platforms targeting 2925 unique proteins by 2943 assays, of which 2923 unique proteins mapped to a protein encoding locus in genome assembly GRCh37. Details regarding the assay have been 489 490 have been described in detail (80). Briefly, proteins are targeted by two separate unique antibodies, each of which are labelled with complementary single stranded oligonucleotides 491 (proximity extension assays (81)). These proximity extension assays hybridization occurs 492 subsequent to the binding of antibody pairs with complementary oligonucleotides which can be 493 quantified using next generation sequencing (NGS). NGS read-outs undergo quality control 494 495 procedures where internal (incubation, extension and amplification controls) and external 496 (negative, plate and sample controls) controls are included. Normalized protein expression (NPX) 497 units are generated by normalization to the extension control and further normalization to the plate control and reported on a log2 scale. We excluded 3 samples as they were shown to be 498 499 extreme outliers using principal component analysis from their entire proteomic profiles. For 500 downstream genetic analysis (fine-mapping and region-based association analysis) we first rankinverse normal transformed NPX-values and corrected for age, sex, and the first ten genetic 501

502 principal components using linear regression models. The residuals of this analysis were used 503 throughout the study.

504

505 Genotyping

506 EPIC-Norfolk samples (n=21,448) were genotyped on the Affymetrix UK Biobank Axiom array chip 507 by Cambridge Genomic Services, University of Cambridge, UK. Sample and variant QC followed 508 the Affymetrix Best Practices guidelines. Samples were excluded based on DishQC < 0.82(fluorescence signal contrast), call-rate <97%, heterozygosity outliers and sex discordance 509 checks. Variants were excluded if call-rate <95% or HWE<=1e-6. Monomorphic variants and those 510 with cluster problems detected using Affymetrix SNPolisher were excluded. Genotype imputation 511 512 was performed using two different reference panels, the Haplotype Reference Consortium (HRC) (release 1) reference panel and the combined UK10K+1000 Genomes Phase 3 reference panel. 513 After pre-imputation QC, 21,044 samples remained for imputation. All SNPs imputed using the 514 515 HRC reference panel were included, and additional variants imputed using only the UK10K+1000 516 Genomes reference panel were added to create a combined imputed set. Variants with imputation quality INFO < 0.4 or MAF of < < 0.0001 were excluded. All positions are on genome 517 assembly GRCh37. After excluding ancestry outliers, individuals without a high-quality proteomic 518 519 profile for each panel and pruning the sample set for related individuals, 1,180 and 1,178 individuals were included in proteogenomic analyses for Olink Explore 1536 and Explore 520 Expansion platforms, respectively. 521

522

#### 523 Fine mapping

We used statistical fine-mapping as implemented in the 'sum of single effects' model (SuSiE) (82) using individual level genotype and protein data to identify credible sets at protein encoding loci (±500kb). Briefly, SuSiE employs a Bayesian framework for variable selection in a multiple regression problem with the aim to identify sets of independent variants each of which likely contain the true causally underlying genetic variant (82). We implemented the workflow using the R package *susieR* (v.0.11.92) and default prior and parameter settings. However, we noticed that SuSiE sometimes reports overlapping credible sets or credible sets that contained variants in high LD with already selected ones. Therefore, we adopted a grid search by first iterating the maximum number of credible sets from 2 to 10 (*L* in SuSiE terminology) and subsequently selecting the output for the maximum *L* so that none of the credible sets reported variants in LD ( $r^2>0.1$ ). We further tested for independent effects of all lead credible set variants (selecting using highest posterior inclusion probability) by including them in a joint regression model. We only report credible sets which showed genome-wide significance ( $p<5x10^{-8}$ ) in those joint models. We used R v.4.1 to compute regression models.

538

## 539 Region-based association testing

To complement fine-mapping analysis, we computed regional association statistics at protein coding loci (±500kb) using fastGWA software provided by GCTA (v. 1.93.2beta) (83). To account for the different selection designs of the sub- and the case-cohort, we performed these analyses within each cohort separately and combined in an inverse-variance fixed-effects meta-analysis in METAL (84).

545

# 546 Gene, Variant, and Protein annotation

547 We obtained conservation scores for all protein coding genes from gnomAD. We used the Variant 548 Effect Predictor software (22) (version 98.3) with the --pick option to annotate all independent 549 lead variants and proxies (r<sup>2</sup>>0.6) of identified pQTLs in our data set and report possible 550 functional consequences. We collapsed pQTLs mapping to the same functional variant to reduce 551 redundancy. We further obtained protein characteristics, e.g., glycosylation sites, from UniProt 552 (85).

553

# 554 Annotation of GWAS catalog loci

We downloaded genome-wide significant summary statistics from the GWAS catalog (date 23/03/2022; (1)) and tested whether any of the lead credible set variants (cis-pQTLs) or proxies (r<sup>2</sup>>0.8) have been reported to be associated with any non-proteomic trait, that is omitting any results that related to multiplex proteomic assays. Out of 347,165 entries (n=9,997 unique traits), 212,628 entries (n=5,391 unique traits) passed this and additional filtering steps (missing effect

estimates, missing risk allele, and not passing genome-wide significance). For each cis-pQTL –
 GWAS variant mapping, we compared the reported or mapped gene (closest gene assigned by
 the GWAS catalog) to the protein-encoding gene at the locus.

563

# 564 Phenome-wide analyses at protein-encoding loci

We performed phenome-wide analyses using statistical colocalization for 914 protein targets 565 where we had evidence for at least one cis-pQTL. To this end, we queried the Open GWAS 566 database (86, 87) using a defined region (±500 kb) around the protein-encoding gene body and 567 tested whether any of the traits in the databases showed a high posterior probability (PP) of 568 569 shared genetic signal with plasma concentrations of the encoded protein target using statistical colocalization (88). We chose a cut-off of PP>80% to declare that a protein target and a 570 phenotypic trait are highly likely to share a genetic signal at a locus. We used a conservative prior 571 setting with p<sub>12</sub>=1x10<sup>-6</sup> and further ensured that regional sentinel variants were in strong LD 572  $(r^2>0.8)$ . To avoid spurious colocalization results due to imperfect overlap of SNPs, we filter all 573 results for which the strongest cis-pQTL or sufficient proxy ( $r^2$ >0.8) in the overlapping set was not 574 included in the overlapping set of SNPs or if less than 500 SNPs were overlapping. We used the 575 576 *igraph* package in R to visualize protein – disease colocalization results as a network to account for cross-disease dependencies established by proteins. 577

578

#### 579 Incorporation of gene expression data

We systematically tested for a shared genetic signal between plasma abundances of a protein 580 and gene expression levels (eQTL) of the protein coding gene in 49 tissues from the GTEx project 581 (v8) (89). We used a similar colocalization framework as described above but adopting a less 582 stringent  $p_{12}$  prior ( $p_{12}=1x10^{-5}$ ) to account for the higher biological prior of genetic signals in the 583 584 protein encoding region. All GTEx variant-gene cis-eQTL and cis-sQTL associations from each downloaded 2020 from 585 tissue were in January https://console.cloud.google.com/storage/browser/gtex-resources. 586

# 588 Phenotypic convergence between pQTL colocalization and rare loss of function gene-burden 589 associations

590 To compare the phenotypic convergence of rare loss of function gene-burden and cis-pQTLs 591 colocalization results, we downloaded single variant and gene-burden results for 3,986 592 phenotypic outcomes from UK Biobank respectively which were analysed by Backman et al. (2021) (downloaded on: 07/12/2021); (64). We filtered the results for 2,939 protein coding genes 593 594 covered by the Olink Explore 1536 and Explore Expansion platforms. We compared the 595 phenotypic convergence of genes that were significant for at least one phenotypic outcome in the exome-wide association analysis at exome-wide significance ( $p<1x10^{-6}$ ) with the pQTLs that 596 597 showed significant statistical colocalization for at least one trait (PP>80%). If ExWAS results were 598 significant for more than one variant group for the same gene - trait association, we have filtered 599 the results to only take forward the most significant finding.

#### 600 Multitrait colocalisation

We used hypothesis prioritisation in multi-trait colocalisation (HyPrColoc) (90) at selected protein 601 602 loci to identify a shared genetic signal across various traits, including gene expression, plasma protein levels, and prioritized phenotypes from the disease-wise colocalization framework. 603 HyPrColoc provides for each cluster three different types of output: 1) a posterior probability (PP) 604 605 that all phenotypes in the cluster share a common genetic signal, 2) a regional association probability, that it, that all the phenotypes share an association with one or more variants in the 606 607 region, and 3) the proportion of the PP explained by the candidate variant. We considered a highly likely alignment of a genetic signal across various phenotypes if the PP>80% and report 608 609 obtained PPs otherwise.

### 610 References

Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The
 NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and
 summary statistics 2019. Nucleic Acids Res. 2019;47(D1):D1005-D12.

Barbeira AN, Bonazzola R, Gamazon ER, Liang Y, Park Y, Kim-Hellmuth S, et al. Exploiting
the GTEx resources to decipher the mechanisms at GWAS loci. Genome Biol. 2021;22(1):49.

Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shoresh N, Adrian J, et al. Expanded
encyclopaedias of DNA elements in the human and mouse genomes. Nature.
2020;583(7818):699-710.

Abell NS, DeGorter MK, Gloudemans MJ, Greenwald E, Smith KS, He Z, et al. Multiple
causal variants underlie genetic associations in humans. Science. 2022;375(6586):1247-54.

5. Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017;8:14357.

624 6. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of 625 the human plasma proteome. Nature. 2018;558(7708):73-9.

Folkersen L, Fauman E, Sabater-Lleal M, Strawbridge RJ, Frånberg M, Sennblad B, et al.
Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet.
2017;13(4):e1006706.

8. Yao C, Chen G, Song C, Keefe J, Mendelson M, Huan T, et al. Author Correction: Genomewide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun. 2018;9(1):3853.

632 9. Gilly A, Park YC, Png G, Barysenka A, Fischer I, Bjørnland T, et al. Whole-genome 633 sequencing analysis of the cardiometabolic proteome. Nat Commun. 2020;11(1):6336.

Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et
al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet.
2021;53(12):1712-21.

637 11. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ,

et al. A genome-wide association study of serum proteins reveals shared loci with commondiseases. Nat Commun. 2022;13(1):480.

Katz DH, Tahir UA, Bick AG, Pampana A, Ngo D, Benson MD, et al. Whole Genome
Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into
Cardiovascular Disease. Circulation. 2022;145(5):357-70.

Png G, Barysenka A, Repetto L, Navarro P, Shen X, Pietzner M, et al. Mapping the serum
proteome to neurological diseases using whole genome sequencing. Nat Commun.
2021;12(1):7042.

Pietzner M, Wheeler E, Carrasco-Zanini J, Kerrison ND, Oerton E, Koprulu M, et al.
Synergistic insights into human health from aptamer- and antibody-based proteomic profiling.
Nat Commun. 2021;12(1):6822.

Pietzner M, Wheeler E, Carrasco-Zanini J, Cortes A, Koprulu M, Wörheide MA, et al.
Mapping the proteo-genomic convergence of human diseases. Science.
2021;374(6569):eabj1541.

16. Zhang J, Dutta D, Köttgen A, Tin A, Schlosser P, Grams ME, et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 2022;54(5):593-602.

655 17. Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Genetic regulation of Biobank 656 the human plasma proteome in 54,306 UK participants. bioRxiv. 657 2022:2022.06.17.496443.

Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman Å, Schork A, et al. Genomic and
drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat Metab.
2020;2(10):1135-48.

19. Enroth S, Johansson A, Enroth SB, Gyllensten U. Strong effects of genetic and lifestyle
factors on biomarker variation and use of personalized cutoffs. Nat Commun. 2014;5:4684.

Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection
in regression, with application to genetic fine mapping. Journal of the Royal Statistical Society:
Series B (Statistical Methodology). 2020;82(5):1273-300.

Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, et al. EPIC-Norfolk: study design
and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer.
1999;80 Suppl 1:95-103.

669 22. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant
670 Effect Predictor. Genome Biol. 2016;17(1):122.

Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al. Discovery of 318
new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in
a multi-ancestry meta-analysis. Nat Genet. 2020;52(7):680-91.

Spracklen CN, Horikoshi M, Kim YJ, Lin K, Bragg F, Moon S, et al. Identification of type 2
diabetes loci in 433,540 East Asian individuals. Nature. 2020;582(7811):240-5.

Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry
genetic study of type 2 diabetes highlights the power of diverse populations for discovery and
translation. Nat Genet. 2022;54(5):560-72.

679 26. McDonald TJ, Nilsson G, Vagne M, Ghatei M, Bloom SR, Mutt V. A gastrin releasing peptide
680 from the porcine nonantral gastric tissue. Gut. 1978;19(9):767-74.

681 27. McDonald TJ, Jörnvall H, Nilsson G, Vagne M, Ghatei M, Bloom SR, et al. Characterization 682 of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem Biophys Res 683 Commun. 1979;90(1):227-33.

Ladenheim EE, Taylor JE, Coy DH, Moore KA, Moran TH. Hindbrain GRP receptor blockade
antagonizes feeding suppression by peripherally administered GRP. Am J Physiol. 1996;271(1 Pt
2):R180-4.

Ladenheim EE, Hampton LL, Whitney AC, White WO, Battey JF, Moran TH. Disruptions in
feeding and body weight control in gastrin-releasing peptide receptor deficient mice. J
Endocrinol. 2002;174(2):273-81.

30. Persson K, Gingerich RL, Nayak S, Wada K, Wada E, Ahrén B. Reduced GLP-1 and insulin
responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. Am J
Physiol Endocrinol Metab. 2000;279(5):E956-62.

Gutzwiller JP, Drewe J, Hildebrand P, Rossi L, Lauper JZ, Beglinger C. Effect of intravenous
human gastrin-releasing peptide on food intake in humans. Gastroenterology. 1994;106(5):116873.

Mhalhal TR, Washington MC, Newman KD, Heath JC, Sayegh AI. Combined gastrin
releasing peptide-29 and glucagon like peptide-1 reduce body weight more than each individual
peptide in diet-induced obese male rats. Neuropeptides. 2018;67:71-8.

- 33. Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjálmsson BJ, Finucane HK, Salem RM, et al.
  Efficient Bayesian mixed-model analysis increases association power in large cohorts. Nat Genet.
  2015;47(3):284-90.
- Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, et al. Million Veteran
  Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol.
  2016;70:214-23.
- Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis
  of genome-wide association studies for body fat distribution in 694 649 individuals of European
  ancestry. Hum Mol Genet. 2019;28(1):166-74.
- Frullanti E, Berking C, Harbeck N, Jézéquel P, Haugen A, Mawrin C, et al. Meta and pooled
  analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev.
  2011;20(4):340-7.
- 37. Chou CH, Hsieh MJ, Chuang CY, Lin JT, Yeh CM, Tseng PY, et al. Functional FGFR4
  Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility. Oncotarget.
  2017;8(56):96225-38.
- Xiong SW, Ma J, Feng F, Fu W, Shu SR, Ma T, et al. Functional FGFR4 Gly388Arg
  polymorphism contributes to cancer susceptibility: Evidence from meta-analysis. Oncotarget.
  2017;8(15):25300-9.
- 39. Ulaganathan VK, Sperl B, Rapp UR, Ullrich A. Germline variant FGFR4 p.G388R exposes a
  membrane-proximal STAT3 binding site. Nature. 2015;528(7583):570-4.
- 40. Shin DJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile
  acid metabolism and insulin action. J Biol Chem. 2009;284(17):11110-20.

41. Ge H, Zhang J, Gong Y, Gupte J, Ye J, Weiszmann J, et al. Fibroblast growth factor receptor
4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced

723 obesity conditions. J Biol Chem. 2014;289(44):30470-80.

42. Wu X, Ge H, Lemon B, Weiszmann J, Gupte J, Hawkins N, et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad

726 Sci U S A. 2009;106(34):14379-84.

Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL. FGFR4 prevents hyperlipidemia and
insulin resistance but underlies high-fat diet induced fatty liver. Diabetes. 2007;56(10):2501-10.

44. Lutz SZ, Hennige AM, Peter A, Kovarova M, Totsikas C, Machann J, et al. The
Gly385(388)Arg Polymorphism of the FGFR4 Receptor Regulates Hepatic Lipogenesis Under
Healthy Diet. J Clin Endocrinol Metab. 2019;104(6):2041-53.

Micha R, Khatibzadeh S, Shi P, Fahimi S, Lim S, Andrews KG, et al. Global, regional, and
national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis
including 266 country-specific nutrition surveys. BMJ. 2014;348:g2272.

46. Lappalainen T, MacArthur DG. From variant to function in human disease genetics.
Science. 2021;373(6562):1464-8.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev
Dis Primers. 2018;4(1):43.

48. Consortium IMSG. Multiple sclerosis genomic map implicates peripheral immune cellsand microglia in susceptibility. Science. 2019;365(6460).

Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, et al. Meta-analysis of 208370 East
Asians identifies 113 susceptibility loci for systemic lupus erythematosus. Ann Rheum Dis.
2021;80(5):632-40.

Kaneko KJ, Kohn MJ, Liu C, DePamphilis ML. The acrosomal protein Dickkopf-like 1 (DKKL1)
is not essential for fertility. Fertil Steril. 2010;93(5):1526-32.

51. Uhlen M, Karlsson MJ, Zhong W, Tebani A, Pou C, Mikes J, et al. A genome-wide
transcriptomic analysis of protein-coding genes in human blood cells. Science. 2019;366(6472).

52. Orrù V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, et al. Complex genetic signatures

in immune cells underlie autoimmunity and inform therapy. Nat Genet. 2020;52(10):1036-45.

53. Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PA. B cells in multiple sclerosis
- from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021;17(7):399414.

54. Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, et al.
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple
Sclerosis. JAMA Neurol. 2018;75(3):320-7.

de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, et al. Common
variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nat Commun.
2021;12(1):3417.

759 56. Richardson TG, Sanderson E, Elsworth B, Tilling K, Davey Smith G. Use of genetic variation
760 to separate the effects of early and later life adiposity on disease risk: mendelian randomisation
761 study. BMJ. 2020;369:m1203.

57. Liu H, Leo C, Chen X, Wong BR, Williams LT, Lin H, et al. The mechanism of shared but
distinct CSF-1R signaling by the non-homologous cytokines IL-34 and CSF-1. Biochim Biophys
Acta. 2012;1824(7):938-45.

58. Delaney C, Farrell M, Doherty CP, Brennan K, O'Keeffe E, Greene C, et al. Attenuated CSF1R signalling drives cerebrovascular pathology. EMBO Mol Med. 2021;13(2):e12889.

767 59. Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, et al. An atlas of genetic 768 influences on osteoporosis in humans and mice. Nat Genet. 2019;51(2):258-66.

60. Lotta LA, Wittemans LBL, Zuber V, Stewart ID, Sharp SJ, Luan J, et al. Association of Genetic
Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary
Disease, and Cardiovascular Risk Factors. JAMA. 2018;320(24):2553-63.

Acosta-Herrera M, Kerick M, González-Serna D, Wijmenga C, Franke A, Gregersen PK, et
al. Genome-wide meta-analysis reveals shared new *loci* in systemic seropositive rheumatic
diseases. Ann Rheum Dis. 2019;78(3):311-9.

Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, Chen WM, Santa Cruz DF, Yang H, et al.
Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and
drug targets for type 1 diabetes. Nat Genet. 2021;53(7):962-71.

778 63. Clarke LA, Giugliani R, Guffon N, Jones SA, Keenan HA, Munoz-Rojas MV, et al. Genotype-

phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International

780 MPS I Registry. Clin Genet. 2019;96(4):281-9.

64. Backman JD, Li AH, Marcketta A, Sun D, Mbatchou J, Kessler MD, et al. Exome sequencing
and analysis of 454,787 UK Biobank participants. Nature. 2021;599(7886):628-34.

783 65. Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, et al.

Advancing human genetics research and drug discovery through exome sequencing of the UK
Biobank. Nat Genet. 2021;53(7):942-8.

786 66. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human
787 genetics. Nat Rev Drug Discov. 2013;12(8):581-94.

Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, et al. Common
variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41(1):56-65.

790 68. Lemke G. How macrophages deal with death. Nat Rev Immunol. 2019;19(9):539-49.

69. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4
as a phosphatidylserine receptor. Nature. 2007;450(7168):435-9.

70. Kuchroo VK, Dardalhon V, Xiao S, Anderson AC. New roles for TIM family members in
immune regulation. Nat Rev Immunol. 2008;8(8):577-80.

795 71. Mouse Genome Database (MGD) at the Mouse Genome Informatics website, The 796 Jackson Laboratory 2022 [Available from: http://www.informatics.jax.org/.

797 72. Fazio S, Hasty AH, Carter KJ, Murray AB, Price JO, Linton MF. Leukocyte low density 798 lipoprotein receptor (LDL-R) does not contribute to LDL clearance in vivo: bone marrow 799 transplantation studies in the mouse. J Lipid Res. 1997;38(2):391-400.

73. Magalhaes MS, Smith P, Portman JR, Jackson-Jones LH, Bain CC, Ramachandran P, et al.
Role of Tim4 in the regulation of ABCA1. Nat Commun. 2021;12(1):4434.

Koelwyn GJ, Corr EM, Erbay E, Moore KJ. Regulation of macrophage immunometabolism
in atherosclerosis. Nat Immunol. 2018;19(6):526-37.

Foks AC, Engelbertsen D, Kuperwaser F, Alberts-Grill N, Gonen A, Witztum JL, et al.
Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein ReceptorDeficient Mice. Arterioscler Thromb Vasc Biol. 2016;36(3):456-65.

76. Alsheikh AJ, Wollenhaupt S, King EA, Reeb J, Ghosh S, Stolzenburg LR, et al. The landscape
of GWAS validation; systematic review identifying 309 validated non-coding variants across 130
human diseases. BMC Med Genomics. 2022;15(1):74.

77. Gudmundsson S, Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, et al.
Addendum: The mutational constraint spectrum quantified from variation in 141,456 humans.
Nature. 2021;597(7874):E3-E4.

78. Mostafavi H, Spence JP, Naqvi S, Pritchard JK. Limited overlap of eQTLs and GWAS hits
due to systematic differences in discovery. bioRxiv. 2022:2022.05.07.491045.

79. Akbari P, Gilani A, Sosina O, Kosmicki JA, Khrimian L, Fang YY, et al. Sequencing of 640,000
exomes identifies *GPR75* variants associated with protection from obesity. Science.
2021;373(6550).

818 80. Zhong W, Edfors F, Gummesson A, Bergström G, Fagerberg L, Uhlén M. Next generation 819 plasma proteome profiling to monitor health and disease. Nat Commun. 2021;12(1):2493.

820 81. Assarsson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D, et al. 821 Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent 822 scalability. PLoS One. 2014;9(4):e95192.

823 82. Wang G, Sarkar A, Car bonetto P, S tephens M. A simple new approach to variable
824 selection in regression, with application to genetic fine mapping. Royal Statistical Society; 2020.
825 p. 1273-300.

83. Jiang L, Zheng Z, Qi T, Kemper KE, Wray NR, Visscher PM, et al. A resource-efficient tool
for mixed model association analysis of large-scale data. Nat Genet. 2019;51(12):1749-55.

828 84. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide 829 association scans. Bioinformatics. 2010;26(17):2190-1.

830 85. Consortium U. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res.
831 2021;49(D1):D480-D9.

832 86. Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU 833 OpenGWAS data infrastructure. bioRxiv. 2020:2020.08.10.244293.

87. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
platform supports systematic causal inference across the human phenome. Elife. 2018;7.

836 88. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.

Bayesian test for colocalisation between pairs of genetic association studies using summary
statistics. PLoS Genet. 2014;10(5):e1004383.

- 839 89. Consortium G. The GTEx Consortium atlas of genetic regulatory effects across human
- 840 tissues. Science. 2020;369(6509):1318-30.
- 841 90. Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, et al. A fast and efficient 842 colocalization algorithm for identifying shared genetic risk factors across multiple traits. Nat
- 843 Commun. 2021;12(1):764.
- 844

#### 846 Acknowledgements

847 The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the 848 Medical Research Council (MR/N003284/1 MC-UU 12015/1 and MC UU 00006/1) and Cancer 849 Research UK (C864/A14136). The genetics work in the EPIC-Norfolk study was funded by the 850 Medical Research Council (MC PC 13048). We are grateful to all the participants who have been 851 part of the project and to the many members of the study teams at the University of Cambridge 852 including the EPIC-Norfolk investigators, the Study Co-ordination team, the Epidemiology Field, 853 Data and Laboratory teams who have enabled this research. Proteomics measurements were 854 supported by a collaboration agreement between the University of Cambridge and Olink. We 855 thank Philippa Pettingill, Ida Grundberg and Janet Kenyon for their support with quality control 856 on the proteomic data. M.K. is supported by Gates Cambridge Trust. JCZS is supported by a 4-857 year Wellcome Trust PhD Studentship and the Cambridge Trust. C.L., E.W., M.P., N.K. and N.J.W. 858 are funded by the Medical Research Council (MC UU 00006/1). The authors thank Million 859 Veteran Program (MVP) staff, researchers, and volunteers, who have contributed to MVP, and 860 especially participants who previously served their country in the military and now generously 861 agreed to enroll in the study (see https://www.research.va.gov/mvp/ for more details). We thank 862 Friedemann Paul, Aroon Hingorani and Siamon Gordon for sharing their expertise on disease-863 specific examples.

864

#### 865 Competing interests

866 E.W. is now an employee of AstraZeneca.

867

#### 868 Author contributions

MK, MP and CL designed the analysis and drafted the manuscript. MK, MP and EW have performed the bioinformatics analyses. JCZS and NK have performed the quality control and data preparation of the proteomic data. SL contributed to the interpretation and curation of disease

- examples. NJW is PI of the EPIC-Norfolk study. All authors contributed to the interpretation of
- the results and critically reviewed the manuscript.

874

# 875 Data availability

- 876 The EPIC-Norfolk data can be requested by bona fide researchers for specified scientific purposes
- via the study website (<u>https://www.mrc-epid.cam.ac.uk/research/studies/epic-norfolk/</u>). Data
- 878 will either be shared through an institutional data sharing agreement or arrangements will be
- made for analyses to be conducted remotely without the need for data transfer.
- Fine-mapped summary statistics for protein coding regions will be shared publicly followingpublication.
- 882 Genome-wide association studies for anthropometric phenotypes have been conducted using
- the UK Biobank resource (application no. 44448). Access to the UK Biobank genotype and
- 884 phenotype data is open to all approved health researchers (http://www.ukbiobank.ac.uk/).